Галазепам

Long-acting benzodiazepine with anxiolytic effect. It is metabolised to N-desmethyldiazepam/nordazepam (Jochemsen 1984).
Indicated in the control of anxiety.
Oral administration every 6 to 8 hours.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data does not make it easy to accurately predict possible transfer to breastmilk, because while its high percentage of protein binding and large volume of distribution would prevent it, the long half-life of its active metabolite (Jochemsen 1984) would facilitate it.

It has very few bibliographical references, and is marketed in few countries

The occasional use and low doses of benzodiazepines are compatible with breastfeeding (Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Kanto 1982).

It is advisable to choose a short-acting benzodiazepine and minimal effective dose as possible (Rowe 2013), especially in the neonatal period and in case of prematurity because they can accumulate in the infant during chronic use (Sachs 2013).

It is advisable to monitor drowsiness and adequate feeding of the infant.
It is not recommended to share a bed (co-sleeping, bed-sharing) with the baby if this drug is being taken, due to increased risk of asphyxia or sudden infant death (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006).

See below the information of this related product:

• Nordazepam (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)